Emerging drugs for age-related macular degeneration

Bibliography

• KLAVER D, WOLFS R, VINGERLING J, HOFFMAN A, DE JONG PT: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam study. Arch. Ophthalmol. (1998) 116(5):653-658.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN DS, O’COLMAIN BJ, MUNOZ B et al.: Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. (2004) 122(4):564-572.
   PubMed Web of Science ®Google Scholar
• SLAKTER JS, STUR M: Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv. Ophthalmol. (2005) 50:263-273.
   PubMed Web of Science ®Google Scholar
• ROVNER BW, ZISSELMAN PM, SHMUELY-DULITZKI Y: Depression and disability in older people with impaired vision: a follow-up study. J. Am. Geriatr. Soc. (1996) 44:181-184.
   PubMed Web of Science ®Google Scholar
• KLEIN BE, KLEIN R, LEE KE et al.: Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. Ophthalmology (1998) 106:160-164.
   Web of Science ®Google Scholar
• LESKE MC, WU SY, HENNIS A et al.: Nine-year incidence of age-related macular degeneration in the Barbados Eye Studies. Ophthalmology (2006) 113(1):29-35.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BE, JENSEN SC, MEUER SM: The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology (1997) 104(1):7-21.
   PubMed Web of Science ®Google Scholar
• KHAN JC, THURLBY DA, SHAHID H et al.: Smoking and age related macular degeneration: the number of packs years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br. J. Ophthalmol. (2006) 90(1):75-80.
   PubMed Web of Science ®Google Scholar
• KLEIN RJ, ZEISS C, CHEW EY et al.: Complement factor H polymorphism in age-related macular degeneration. Science (2005) 308:385-389.
   PubMed Web of Science ®Google Scholar
• RIVERA A, FISHER SA, FRITSCHE LG et al.: Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independenly of complement factor H to disease risk. Hum. Mol. Genet. (2006) 14:3227-3236.
   Web of Science ®Google Scholar
• SEDDON JM, COTE J, DAVIS N, ROSNER B: Progression of age-related macular degeneration association with body mass index, waist circumference, and waist-hip ratio. Arch. Ophthalmol. (2003) 121(6):785-792.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN R, IKRAM MK, VINGERLING JR, WITTEMAN JC, HOFMAN A, DE JONG PT: Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest. Ophthalmol. Vis. Sci. (2003) 44(9):3771-3777.
   PubMed Web of Science ®Google Scholar
• SEDDON JM, ROSNER B, SPERDUTO RD et al.: Dietary fat and risk for advanced age-related macular degeneration. Arch. Ophthalmol. (2001) 119(8):1191-1199.
   PubMed Web of Science ®Google Scholar
• IKRAM MK, VAN LEEUWEN R, VINGERLING JR, HOFMAN A, DE JONG PT: Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest. Ophthalmol. Vis. Sci. (2003) 44(9):3778-3782.
   PubMed Web of Science ®Google Scholar
• WANG JJ, KLEIN R, SMITH W, KLEIN BE, TOMANY S, MITCHELL P: Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam And Blue Mountains eye studies. Ophthalmology (2003) 110(10):1960-1967.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BE, WONG TY, TOMANY SC, CRUICKSHANKS KJ: The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Arch. Ophthalmol. (2002) 120(11):1551-1558.
   PubMed Web of Science ®Google Scholar
• MILLER DM, ESPINOSA-HEIDMANN DG, LEGRA J et al.: The association of prior cytomegalovirus infection with neovascular age-related macular degeneration. Am. J. Ophthalmol. (2004) 138(3):323-328.
   PubMed Web of Science ®Google Scholar
• KALAYOGLU MV, BULA D, ARROYA J, GRAGOUDAS ES, D’AMICO D, MILLER JW: Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. Arch. Clin. Exp. Opthalmol. (2005) 243(11):1080-1090.
   PubMed Web of Science ®Google Scholar
• MARSHALL J: The ageing retina: physiology or pathology. Eye (1987) 1:282-295.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, DICK HB, OFFERMAN I, SCHMIDT-ERFURTH U: The significance of oxidative mechanisms in diseases of the retina. Klin. Monatsbl. Augenheilkd. (2002) 219(9):631-643.
   PubMed Web of Science ®Google Scholar
• PENFOLD PL, MADIGAN MC, GILLIES MC, PROVIS JM: Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye Res. (2001) 20(3):385-414.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch. Ophthalmol. (1997) 115(6):741-747.
   PubMed Web of Science ®Google Scholar
• BRESSLER SB, MAGUIRE MG, BRESSLER NM, FINE SL: Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. the macular photocoagulation study group. Arch. Ophthalmol. (1990) 108(10):1442-1447.
   PubMed Web of Science ®Google Scholar
• GREEN WR, ENGER C: Age-related macular degeneration histopathologic studies. The 1992 Lorenz E Zimmerman lecture. Ophthalmology (1993) 100:1519-1535.
   PubMed Web of Science ®Google Scholar
• MACULAR PHOTOCOAGULATION STUDY GROUP: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol. (1991) 109:1220-1231.
   PubMed Web of Science ®Google Scholar
• CHAKRAVARTHY U, SOUBRANE G, BANDELLO F et al.: Evolving European guidance on the medical management of neovascular age related macular degeneration. Br. J. Ophthalmol. (2006) 90(9):1188-1196.
   PubMed Web of Science ®Google Scholar
• ABDEL-MEGUID A, LAPPAS A, HARTMANN K et al.: One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br. J. Ophthalmol. (2003) 87(5):615-621.
   PubMed Web of Science ®Google Scholar
• ECKARDT C, ECKARDT U, CONRAD HG: Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (1999) 237(4):313-325.
   PubMed Web of Science ®Google Scholar
• BARAK A, HAUSER D, YIPP P et al.: A Phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration. Br. J. Radiol. (2005) 78(933):827-831.
   PubMed Web of Science ®Google Scholar
• NEWSOM RS, MCALISTER JC, SAEED M, EL-GHONEMY K, MCHUGH JD: Results 28 months following transpupillary thermotherapy for classic and occult choroidal neovascularization in patients with age-related macular degeneration. Ophthalmic Surg. Lasers Imaging (2005) 36(2):94-102.
   PubMed Web of Science ®Google Scholar
• BRESSLER NM, TAP STUDY GROUP: Photodynamic therapy of subfoveal choroidal neovasculariation in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. (2001) 119(2):198-207.
   PubMed Web of Science ®Google Scholar
• KAISER PK; TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY (TAP) STUDY GROUP: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomised clinical trials with an open-label extension TAP Report No.8. Graefes Arch. Clin. Exp. Ophthalmol. (2006) 244(9):1132-1142.
   PubMed Web of Science ®Google Scholar
• VERTEPORFIN IN PHOTODYNAMIC THERAPY STUDY GROUP: Verteporfin therapy of subfoveal choroidal neovascularisation in age-related macular degeneration: two-year results of a randomised clinical trial including lesions with occult with no classic chouridal neovascularisation – verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. (2001) 131(5):541-560.
   PubMed Web of Science ®Google Scholar
• WRITING COMMITTEE FOR THE TAP STUDY GROUP: Improvement after verteporfin therapy. Arch. Ophthalmol. (2003) 121:415-416.
   PubMed Web of Science ®Google Scholar
• SMITH DH, FENN P, DRUMMOND M: Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br. J. Ophthalmol. (2004). 88:1107-1112.
   PubMed Web of Science ®Google Scholar
• HOPLEY C, SALKELD G, MITCHELL P: Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br. J. Ophthalmol. (2004). 88:982-987.
   PubMed Web of Science ®Google Scholar
• MENNEL S, PETER S, MEYER CH, THUMANN G: Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch. Clin. Exp. Ophthalmol. (2006) 244(8):1015-1021.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-EURFURTH U, SCHOLTZER-SCHREHARD U, CURSIEFEN C, MICHELS S, BECKENDORF A, NAUMAN GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. (2003) 44(10):4473-4480.
   PubMed Web of Science ®Google Scholar
• CHALLA J, GILLIES M, PENFOLD P, GYRORY JF, HUNYOR AB, BILLSON FA: Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust. N. Z. J. Ophthalmol. (1998) 26(4):277-281.
   PubMedGoogle Scholar
• JONAS JB, DEGENRING RF, KREISSIG I, FRIEDEMANN T, AKKOYUN I: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomised study. Eye (2004) 19(2):163-170.
   Web of Science ®Google Scholar
• DANIS RP, CIULLA TA, PRATT LM, ANLIKER W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina (2000) 20(3):244-250.
   PubMed Web of Science ®Google Scholar
• GILLIES M, SIMPSON J, LUO W et al.: A randomised clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration. Arch. Ophthalmol. (2003) 121(5):667-673.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, SCHMIDT-ERFURTH U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology (2006) 113(1):14-22.
   PubMed Web of Science ®Google Scholar
• CHAN WM, LAI TY, WONG AL, TONG JP, LIU DT, LAM DS: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br. J. Ophthalmol. (2006) 90(3):337-341.
   PubMed Web of Science ®Google Scholar
• SPAIDE R, SORENSON J, MARANAN L: Combined photodynamic therapy with vertiporfin and intravitreal triamcinolone acetonide for choroidal neovascularisation. Ophthalmology (2003) 110(8):1517-1525.
   PubMed Web of Science ®Google Scholar
• RECHTMAN E, DANIS RP, PRATT LM, HARRIS A: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br. J. Ophthalmol. (2004) 88(3):344-347.
   PubMed Web of Science ®Google Scholar
• VAN DE MOERE A, SANDHU SS, KAK R, MITCHELL KW, TALKS SJ: Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology (2005) 112(11):1896-1903.
   PubMedGoogle Scholar
• NICOLO M, GHIGLIONE D, LAI S, NASCIUTI F, CICINELLI S, CALABRIA G: Occult with no classis choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina (2006) 26(1):58-64.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, SCHMIDT-ERFUTH U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularisation in age-related macular degeneration. Am. J. Ophthalmol. (2006) 141:638-645.
   PubMed Web of Science ®Google Scholar
• RUIZ-MORENO JA, MONTERO JA, BARILE S, ZARBIN MA: Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina (2006) 26:602-612.
   PubMed Web of Science ®Google Scholar
• BEATTY S, BOULTON M, HENSON D et al.: Macular pigment and age-related macular degeneration. Br. J. Ophthalmol. (1999) 83:867-877.
   PubMed Web of Science ®Google Scholar
• AGE-RELATED EYE DISEASE STUDY RESEARCH GROUP: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch. Opthalmol. (2001) 119:1417-1436.
   PubMed Web of Science ®Google Scholar
• LYNCH KR, WOOLSEY A, HANSEN E, DREYFUS J: Market outlook. In: Age-Related Macular Degeneration. Decision Resources, Waltham, Massachusetts, USA (2006):127-141.
   Google Scholar
• PARFYONOVA YV, PLEKHANOVA OS, TKACHUK VA: Plasminogen activators in vascular remodelling and angiogenesis. Biochem. (Moscow) (2002) 67(1):139-156.
   Google Scholar
• PEPPER MS: Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. (2001) 21(7):1104-1117.
   PubMed Web of Science ®Google Scholar
• NG EWM, ADAMIS AP: Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can. J. Ophthalmol. (2005) 40:352-368.
   PubMed Web of Science ®Google Scholar
• FERRARA N: Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev. (2004) 25(4):581-611.
   PubMed Web of Science ®Google Scholar
• BAROUCH FC, MILLER JW: Anti-vascular endothelial growth factor strategies for the treatment of choroidal neovascularisation from age-related macular degeneration. Internat. Ophthalmol. Clin. (2004) 44:23-30.
   PubMedGoogle Scholar
• KWAK N, OKAMOTO N, WOOD JM, CAMPOCHIARO PA: VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. (2000) 41(10):3158-3164.
   PubMed Web of Science ®Google Scholar
• HAGEMAN GS, ANDERSON DH, JOHNSON LV et al.: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acac Sci. USA (2005) 102:7227-7232.
   PubMed Web of Science ®Google Scholar
• SCHMIDT-ERFURTH U, MICHELS S, BARBAZETTO I, LAQUA H: Photodynamic effects on choroidal neovascularisation and physiological choroid. Invest. Ophthalmol. Vis. Sci. (2002) 43:830-841.
   PubMed Web of Science ®Google Scholar
• MICHELS S, HANSMANN F, GEITZENAUER W, SCHMIDT-ERFURTH U: Influence of treatment parameters on selectivity of verteporfin therapy. Invest. Ophthalmol. Vis. Sci. (2006) 47:371-376.
   PubMed Web of Science ®Google Scholar
• GRAGOUDAS ES, ADAMIS AP, CUNNIGHAM ET, FEINSOD M, GUYER DR: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351(27):2805-2816.
   PubMed Web of Science ®Google Scholar
• D’AMICO DJ; VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (V.I.S.I.O.N.) CLINICAL TRIAL GROUP: VEGF inhibition study in neovascularization (VISION): second year efficacy data. Invest. Ophthalmol. Vis. Sci. (2005) 46:E-Abstract 2309.
   Google Scholar
• CARRASQUILLO KG, RICKER JA, RIGAS IK, MILLER JW, GRAGOUDAS ES, ADAMIS AP: Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic) acid microspheres. Invest. Ophthalmol. Vis. Sci. (2003) 44(1):290-299.
   PubMed Web of Science ®Google Scholar
• GAUDREAULT J, FEI D, RUSIT J, SUBOC P, SHIU V: Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. (2005) 46(2):726-733.
   PubMed Web of Science ®Google Scholar
• ADAMIS AP, SHIMRA DT, TOLENTINO MJ et al.: Inhibition of VEGF prevents ocular neovascularisation in a non-human primate. Arch. Ophthalmol. (1996) 114(1):66-71.
   PubMed Web of Science ®Google Scholar
• MICHELS S, ROSENFELD PJ, PULIAFITO CA, MARCUS EN, VENKATRAMAN AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology (2005) 112(6):1035-1047.
   PubMed Web of Science ®Google Scholar
• MANZANO RP, PEYMAN GA, KHAN P, KIVILEIN M: Intravitreal bevacizumab did not appear toxic to the retina of New Zealand albino rabbits. Retina (2006) 26:257-261.
   PubMed Web of Science ®Google Scholar
• AVERY RL, PIERAMICI DJ, RABENA MD, CASTELLARIN AA, NASIR MA, GIUST MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 113(3):363-372.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN AJ, D’AMICO DJ, MIELER WF, SCHNEEBAUM C, BEASLEY C: Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal chorodial neovascularization in patients with age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. (2005) 243:9-12.
   PubMed Web of Science ®Google Scholar
• DE FALLER JM, CLARK AF: A new pharmacological treatment for angiogenesis. In: Pterygium. Taylor HR (Ed), Kugler Publications, The Hague, The Netherlands (2000)159-181.
   Google Scholar
• SLAKTER JS, BOCHOW T, D’AMICO DJ et al.: Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology (2006) 113(1):3-13.
   PubMed Web of Science ®Google Scholar
• RUSSEL SR, SLAKTER JS, HO AC et al.: Anecortave acetate treatment of ‘dry’ AMD to reduce risk of progression to ‘wet’ AMD – the anecortave acetate risk reduction trial (AART). Invest. Ophthalmol. Vis. Sci. (2004) 45:E-Abstract 3134.
   Google Scholar
• EYETECH STUDY GROUP: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularisation secondary to age-related macular degeneration: Phase II study results. Ophthalmology (2003) 110(5):979-986.
   PubMed Web of Science ®Google Scholar
• COLINA-LUQUEZ JM, LIGGETT PE, TOM D, CHAUDHRY NA, HAFFNER G, CORTES CF: Prospective and preliminary study evaluating triple therapy of intravitreal triamcinolone, photodynamic therapy and pegaptanib sodium for choroidal neovascularisation. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 30 April (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• SCHMIDT-ERFURTH U, GABEL P, HOHMAN T, PROTECT STUDY GROUP: Preliminary results from an open-label, multicenter, Phase II study assessing the effects of same-day administration of ranibizumab (Lucentis™) and verteporfin PDT (PROTECT Study). Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2 May (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• FUNK M, MICHELS S, WAGNER J, KISS C, SACU S, SCHMIDT-ERFURTH U: Vascular effects of combined ranibizumab (Lucentis®) and verteporfin (Visudyne®) therapy in patients with neovascular age-related macular degeneration. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 30 April (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• WAGNER J, SIMADER C, KISS C, MICHELS S, SACU S, SCHMIDT-ERFURTH U: Changes in functional macular mapping in patients with neovascular age-related macular degeneration receiving combination of verteporfin (Visudyne®) and ranibizumab (Lucentis™) therapy. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 30 April (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• WOLF S, GABEL P, HOHMAN TC, SCHMIDT-ERFURTH U: Fluorescein angiographic and OCT results from an open-label, multicenter, phase ii study assessing the effects of same-day ranibizumab (Lucentis™) and verteporfin PDT (Visudyne®). Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 3 May (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• OFFERMANN I, ALTINAY A, SCHMIDT-ERFURTH U, AUGUSTIN AJ: Intravitreal bevacizumab for the treatment of remaining choroidal neovascularisation (CNV) activity following combination therapy (PDT and triamcinolone). Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 1 May (2006); Fort Lauderdale, Florida, USA.
   Google Scholar
• SAISHIN Y, SAISHIN Y, TAKAHASHI K et al.: VEGF-TRAP R1R2 suppresses choroidal neovasculaization and VEGF-induced breakdown of the blood–retinal barrier. J. Cell. Physiol. (2003) 195(2):241-248.
   PubMed Web of Science ®Google Scholar
• WEIGAND SJ, ZIMMER E, NORK TM et al.: VEGF Trap both prevents experimental choroidal neovascularization and causes regression of established lesions in non-human primates. Invest. Ophthalmol. Vis. Sci. (2005) 46:E-Abstract 1411.
   Google Scholar
• CIULLA TA, CRISWELL MH, DANIS RP, WILLIAMS JL, MCLANE MP, HOLROYD KJ: Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina (2003) 23(6):808-814.
   PubMed Web of Science ®Google Scholar
• GARCIA CA, QUIROZ-MERCADO H, UWAYDAT S et al.: A Phase I/II trial for intravenous squalamine lactate for treatment of choroidal neovascularization in age related macular degeneration (ARMD). Invest. Ophthalmol. Vis. Sci. (2004) 45:E-Abstract 2362.
   Google Scholar
• CUILLA TA, REGILLO C, DESAI A, LEVITT R, NAU J, GARCIA CA: A Phase II, multi-center, randomized, controlled, masked study of the effects of squalamine lactate in combination with Visudyne® in patients with subfoveal choroidal neovascularization associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. (2005) 46:E-Abstract 2363.
   Google Scholar
• REICH S, FOSNOT J, KUROKI A et al.: Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. (2003) 9:210-216.
   PubMed Web of Science ®Google Scholar
• SUZUMA K, TAKAHARA N, SUZUMA I et al.: Characterization of protein kinase C beta isoform’s action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation and retinal neovascularisation. Proc. Natl. Acad. Sci. USA (2002) 99(2):721-726.
   PubMed Web of Science ®Google Scholar
• XIA P, AIELLO LP, ISHII H et al.: Characterization of vascular endothelial growth factor’s effect on activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98(9):2018-2026.
   PubMed Web of Science ®Google Scholar
• FABBRO D, RUETZ S, BODIS S et al.: PCK42 a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Des. (2000) 15(1):17-28.
   PubMedGoogle Scholar
• FRANK RN: Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am. J. Ophthalmol. (2002) 133(5):693-698.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, CLERMONT A, ARORA V, DAVIS MD, SHEETZ MJ, BURSELL SE: Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. (2006) 47(1):86-92.
   PubMed Web of Science ®Google Scholar
• KINOSE F, ROSCILLI G, LAMARTINA S et al.: Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol. Vis. (2005) 11:366-373.
   PubMed Web of Science ®Google Scholar
• RAMUSSEN H, CHU KW, CAMPOCHIARO P et al.: Clinical protocol. An open-label, Phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum. Gene Ther. (2001) 12(16):2029-2032.
   PubMedGoogle Scholar
• HONDA M, SAKAMOTO T, ISHIBASHI T, INOMATA H, UENO H: Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. (2000) 7(11):978-985.
   PubMed Web of Science ®Google Scholar